| Name |
Valproate sodium (USAN);Sodium valproate (JP18);Depakene (TN);Selenica (TN) |
| Product |
|
| Generic |
VALPROATE SODIUM (Athenex Pharmaceutical Division), VALPROATE SODIUM (Fresenius Kabi USA), VALPROATE SODIUM (Fresenius Kabi USA), VALPROATE SODIUM (Hikma Pharmaceuticals USA), VALPROATE SODIUM (Hikma Pharmaceuticals USA), VALPROATE SODIUM (Sagent Pharmaceuticals) |
| Formula |
C8H15O2. Na |
| Exact mass |
166.0970 |
| Mol weight |
166.19 |
| Structure |
 |
| Simcomp |
|
| Class |
Cardiovascular agent DG01575 Calcium channel blocker DG01573 Calcium channel T type blockerNeuropsychiatric agent DG03199 Antiepileptic agent DG02035 Fatty acid antiepileptic |
| Remark |
Therapeutic category: 1139 1179ATC code: N03AG01Chemical structure group: DG00849Product (DG00849): D00399<US> D00304<US> D00710<JP/US> |
| Efficacy |
Anticonvulsant, Antimanic, Antimigraine, Antiepileptic |
| Comment |
Fatty acid derivative |
| Target |
ABAT [HSA:18] [KO:K13524]SSADH [HSA:7915] [KO:K00139]GAD [HSA:2571 2572] [KO:K01580]CACNA1-T [HSA:8911 8912 8913] [KO:K04856 K04855 K04854] |
| Pathway |
hsa04020 Calcium signaling pathwayhsa04727 GABAergic synapse |
| Interaction |
|
| Structure map |
map07033 Anticonvulsantsmap07036 Calcium channel blocking drugsmap07048 Antimigraines |
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] N NERVOUS SYSTEM N03 ANTIEPILEPTICS N03A ANTIEPILEPTICS N03AG Fatty acid derivatives N03AG01 Valproic acid D00710 Valproate sodium (USAN) <JP/US>USP drug classification [BR:br08302] Anticonvulsants Anticonvulsants, Other Valproic Acid D00710 Valproate sodium (USAN) Antimigraine Agents Antimigraine Agents, Other Valproic Acid D00710 Valproate sodium (USAN) Bipolar Agents Mood Stabilizers Valproic Acid D00710 Valproate sodium (USAN)Therapeutic category of drugs in Japan [BR:br08301] 1 Agents affecting nervous system and sensory organs 11 Agents affecting central nervous system 113 Antiepileptics 1139 Others D00710 Valproate sodium (USAN); Sodium valproate (JP18) 117 Psychotropics 1179 Others D00710 Valproate sodium (USAN); Sodium valproate (JP18)Drug groups [BR:br08330] Cardiovascular agent DG01575 Calcium channel blocker DG01573 Calcium channel T type blocker DG00849 Valproic acid D00710 Valproate sodium Neuropsychiatric agent DG03199 Antiepileptic agent DG02035 Fatty acid antiepileptic DG00849 Valproic acid D00710 Valproate sodiumDrug classes [BR:br08332] Neuropsychiatric agent DG03199 Antiepileptic agent D00710 Valproate sodiumTarget-based classification of drugs [BR:br08310] Ion channels Voltage-gated ion channels Calcium channels CACNA1-T D00710 Valproate sodium (USAN) <JP/US> Enzymes Oxidoreductases (EC1) Dehydrogenases SSADH D00710 Valproate sodium (USAN) <JP/US> Transferases (EC2) Aminotransferase ABAT D00710 Valproate sodium (USAN) <JP/US> Lyases (EC4) Carboxy-lyases GAD D00710 Valproate sodium (USAN) <JP/US>Drugs listed in the Japanese Pharmacopoeia [BR:br08311] Chemicals D00710 Sodium valproate D00710 Sodium valproate tablets D00710 Sodium valproate extended-release tablets A D00710 Sodium valproate extended-release tablets B D00710 Sodium valproate syrupPharmacogenomic biomarkers [br08341.html] Polymorphisms and mutations affecting drug response D00710Drug groups [BR:br08330] Cardiovascular agent DG01575 Calcium channel blocker DG01573 Calcium channel T type blocker DG00849 Valproic acid Neuropsychiatric agent DG03199 Antiepileptic agent DG02035 Fatty acid antiepileptic DG00849 Valproic acid |
| Other DBs |
CAS: 1069-66-5PubChem: 7847775ChEBI: 9925LigandBox: D00710NIKKAJI: J7.236B |
| LinkDB |
|
| KCF data |
ATOM 11 1 C1c C 24.8619 -18.6957 2 C1b C 24.8619 -17.3175 3 C1b C 23.6530 -19.4139 4 C6a C 26.0650 -19.4139 5 C1b C 23.6472 -16.6109 6 C1b C 22.4441 -18.6957 7 O6a O 27.2738 -18.6957 8 O6a O 26.0650 -20.8098 #- 9 C1a C 22.4384 -17.3175 10 C1a C 21.2412 -19.4139 11 Z Na 28.5001 -20.7280 #+BOND 9 1 1 2 1 2 1 3 1 3 1 4 1 4 2 5 1 5 3 6 1 6 4 7 2 7 4 8 1 8 5 9 1 9 6 10 1 |
